D. Hickey

发表

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.

D. Tew, H. Boyd, D. Dhanak, 1999, The Biochemical journal.

Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.

I. E. Smith, P. Woollard, J. Liddle, 2006, Journal of medicinal chemistry.

Synthesis and properties of macrolones characterized by two ether bonds in the linker.

A. K. Forrest, D. Verbanac, S. Alihodžić, 2010, Bioorganic & medicinal chemistry.

Bile acid sequestrants

G. Benson, D. Hickey, 1994 .

Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy.

D. Tew, Stephen A. Smith, S. Smith, 2001, Farmaco.

Inhibitors of CoA-independent transacylase block the movement of arachidonate into 1-ether-linked phospholipids of human neutrophils.

R. Mayer, L. Marshall, A. Fonteh, 1995, Biochemistry.

Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor.

A. Goetz, A. Peat, D. M. Hickey, 2007, Bioorganic & medicinal chemistry letters.

5-aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

R. Ife, D. M. Hickey, D. Haigh, 2003, Bioorganic & medicinal chemistry letters.

CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.

I. Forbes, P. Groot, R. Ife, 2000, Bioorganic & Medicinal Chemistry Letters.

Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones.

H. Boyd, Stephen A. Smith, I. Stansfield, 2002, Bioorganic & medicinal chemistry letters.

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

Hung‐Yuan Cheng, Stephen A. Smith, I. Stansfield, 2003, Bioorganic & medicinal chemistry letters.

The discovery of GSK221149A: a potent and selective oxytocin antagonist.

Michael J Allen, John Liddle, Fabrizio Nerozzi, 2008, Bioorganic & medicinal chemistry letters.

The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.

Hung‐Yuan Cheng, Stephen A. Smith, I. Stansfield, 2002, Bioorganic & medicinal chemistry letters.

2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2.

D. Tew, H. Boyd, I. Stansfield, 2000, Bioorganic & medicinal chemistry letters.

Octimibate, a potent non‐prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor

T. Rink, J. Macdermot, T. Hallam, 1991, British journal of pharmacology.

Primate vascular responses to octimibate, a non‐prostanoid agonist at the prostacyclin receptor

E. F. Smith, T. Rink, A. Heagerty, 1991, British journal of pharmacology.

N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2.

D. Tew, H. Boyd, I. Stansfield, 2000, Bioorganic & medicinal chemistry letters.

Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.

P. Woollard, D. Brooks, J. Liddle, 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

5-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

M. Saunders, J. Liddle, S. Garland, 2003, Bioorganic & medicinal chemistry letters.